Faeth Therapeutics, Inc.

FTH Nasdaq SEC CIK 1829802
Follow Faeth Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$20.4M −346.4% vs same quarter last year
EPS, diluted −$0.79 +78.2% vs same quarter last year
Operating cash flow −$13M −262.6% vs same quarter last year
Operating income −$22.1M −355.3% vs same quarter last year
Net income by quarter
−$7.8M
−$6.9M
−$4.9M
−$4.6M
−$4.7M
−$170.2M
−$16M
−$20.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$21.1M
FY24−$30.2M
FY23−$34.1M
FY22−$48.6M
FY21−$36.8M
FY20−$20.1M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$20.5M
FY24−$24.8M
FY23−$32.2M
FY22−$39.3M
FY21−$32.3M
FY20−$18.9M
FY19-